References: Emerging Options with Coxib Therapy

References

1. Stähelin HB, Monsch AU, Spiegel R. Early diagnosis of dementia via a two-step screening and diagnostic procedure. Int Psychogeriatr 1997; 9(suppl 1):123-130.

2. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997; 278:1363-1371.

3. van Reekum R, Simard M, Farcnik K. Diagnosis of dementia and treatment of Alzheimer's disease. Pharmacologic management of disease progression and cognitive impairment. Can Fam Physician 1999; 45:945-952.

4. National Center for Chronic Disease Prevention and Health Promotion. United States Department of Health and Human Services Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Cancer Prevention and Control. Colorectal cancer: the importance of prevention and early detection. Available at: http://www.cdc.gov/cancer/colorctl/colorect.htm. Accessed September 25, 2001.

5. Alzheimer's Association. Alzheimer's disease and US population trends are on a collision course. Available at: http://www.alz.org/media/news/current/071301collision.htm. Accessed July 11, 2001.

6. Frederickson RCA, Brunden KR. New opportunities in AD research-roles of immunoinflammatory responses and glia. Alzheimer Dis Assoc Disord 1994; 8:159-165.

7. Luk GD. Prevention of gastrointestinal cancer-the potential role of NSAIDs in colorectal cancer. Schweiz Med Wochenschr 1996; 126:801-812.

8. Chang HM. Cancer pain management. Med Clin North Am 1999; 83:711-736.

9. Eikelenboom P, Rozemuller AJM, Hoozemans JJM, Veerhuis R, van Gool WA. Neuroinflammation and Alzheimer disease: clinical and therapeutic implications. Alzheimer Dis Assoc Disord 2000; 14:S54-S61.

10. McGeer PL. Cyclo-oxygenase-2 inhibitors. Rationale and therapeutic potential for Alzheimer's disease. Drugs & Aging 2000; 17:1-11.

11. Breitner JCS. Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. Neurobiol Aging 1996; 17:789-794.

12. Kaufmann WE, Andreasson KI, Isakson PC, Worley PF. Cyclooxygenases and the central nervous system. Prostaglandins 1997; 54:601-624.

13. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995; 21:195-218.

14. McGeer PL, McGeer E, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet 1990; 335:1037.

15. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry 1994;151:1105-1113.

16. Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T. Alzheimer's disease: a study of epidemiological aspects. Ann Neurol 1984; 15:335-341.

17. French LR, Schuman LM, Mortimer JA, Hutton JT, Boatman RA, Christians B. A case-control study of dementia of the Alzheimer type. Am J Epidemiol 1985; 121:414-421.

18. Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer's disease in Australia. Neurology 1990;40:1698-1707.

19. Li G, Shen YC, Li YT, Chen CH, Zhau YW, Silverman JM. A case-control study of Alzheimer's disease in China. Neurology 1992; 42:1481-1488.

20. McDowell I, Hill G, Lindsay J, et al. The Canadian study of health and aging: risk factors for Alzheimer's disease in Canada. Neurology 1994; 44:2073-2080.

21. Breitner JCS, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 1994; 44:227-232.

22. Breitner JCS, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H-2 blocking drugs. Neurobiol Aging 1995; 16:523-530.

23. McGeer PL, Schulzer M, McGeer EG. Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996; 47:425-432.

24. Beard CM, Kokman E, Kurland LT. Rheumatoid arthritis and susceptibility to Alzheimer's disease. Lancet 1991; 337:1426.

25. Myllykangas-Luosujärvi R, Isomäki H. Alzheimer's disease and rheumatoid arthritis. Br J Rheumatol 1994; 33:501-502.

26. Jenkinson ML, Bliss MR, Brain AT, Scott DL. Rheumatoid arthritis and senile dementia of the Alzheimer's type [letter]. Br J Rheumatol 1989; 28:86-88.

27. Graves AB, White E, Koepsell TD, et al. A case-control study of Alzheimer's disease. Ann Neurol 1990; 28:766-774.

28. Lucca U, Tettamanti M, Forloni G, Spagnoli A. Nonsteroidal antiinflammatory drug use in Alzheimer's disease. Biol Psychiatry 1994; 36:854-856.

29. Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MMB, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 1995; 45:1441-1445.

30. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997; 48:626-632.

31. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995; 45:51-55.

32. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-1611.

33. Rojas-Fernandez C. Indomethacin is inappropriate for use in the geriatric population. Ann Pharmacother 1998; 32:980.

34. Mallet L, Kuyumjian J. Indomethacin-induced behavioral changes in elderly patient with dementia. Ann Pharmacother 1998; 32:201-203.

35. Smalheiser NR, Swanson DR. Indomethacin and Alzheimer's disease. Neurology 1996; 46:583.

36. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999; 53:197-201.

37. Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Neurology 2000; 54:588-593.

38. Pasinetti GM. Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. J Neurosci Res 1998; 54:1-6.

39. Yasojima K, Schwab C, McGeer EG, McGeer PL. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res 1999;830:226-236.

40. Hoozemans JJ, Rozemuller AJM, Janssen I, De Groot CJA, Veerhuis R, Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol (Berl) 2001; 101:2-8.

41. Pasinetti GM, Aisen PS. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 1998; 87:319-324.

42. Pennisi E. Building a better aspirin. Science 1998;280:1191-1192.

43. Sainali SM, Ingram DM, Talwaker S, et al. Results of a doubleblind, placebo-controlled study of celecoxib in the treatment of progression in Alzheimer's disease [abstract]. Sixth International Stockholm-Springfield Symposium of Advances in Alzheimer Therapy, Stockholm, Sweden, April 5-8, 2000.

44. Ziegler J. Early trials probe COX-2 inhibitors' cancer-fighting potential. J Natl Cancer Inst 1999; 91:1186-1187.

45. World Health Organization. The World Health Report 1999: Making a Difference. Geneva, Switzerland. Available at: http://www.who.int/whr/1999/en/report.htm. Accessed December 21, 2001.

46. Wu JS, Fazio VW. Colon cancer. Dis Colon Rectum 2000;43:1473-1486.

47. Thun MJ. NSAID use and decreased risk of gastrointestinal cancers. Gastroenterol Clin North Am 1996; 25:333-348.

48. Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342:1946-1952.

49. Oshima M, Murai (Hata) N, Kargman S, et al. Chemoprevention of intestinal polyposis in the ApcD716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001;61:1733-1740.

50. Williams CS, Luongo C, Radhika A, et al. Elevated cyclooxygenase- 2 levels in Min mouse adenomas. Gastroenterology 1996;111:1134-1140.

51. DuBois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996; 110:1259-1262.

52. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107:1183-1188.

53. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93:705-716.

54. Giardiello FM. NSAID-induced polyp regression in familial adenomatous polyposis patients. Gastroenterol Clin North Am 1996;25:349-361.

55. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A 1998; 95:681-686.

56. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E in human colon cancer cells. Cancer Res 1998; 58:362-366.

57. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105:1589-1594.

58. Jacoby RF, Marshall DJ, Newton MA, et al. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 1996; 56:710-714.

59. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996; 56:2556-2560.

60. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58:409-412.

61. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328:1313-1316.

62. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993; 80:1618-1619.

63. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101:635-639.

64. Bresalier RS. Chemoprevention comes to clinical practice: COX-2 inhibition in familial adenomatous polyposis. Gastroenterology 2000;119:1797-1798.

65. McDonnell FJ, Sloan JW, Hamann SR. Advances in cancer pain management. Curr Pain Headache Rep 2001; 5:265-271.

66. Cherny NI, Portenoy RK. Practical issues in the management of cancer pain. In: Wall PD, Melzack R, editors. Textbook of Pain. 4th ed. New York, NY: Churchill Livingston, 1999:1479-1522.

67. Cherny NI. The management of cancer pain. CA Cancer J Clin 2000; 50:70-116.

68. Olson KB, Pienta KJ. Pain management in patients with advanced prostate cancer. Oncology (Huntingt) 1999;13:1537-1550.

69. Jenkins CA, Bruera E. Nonsteroidal anti-inflammatory drugs as adjuvant analgesics in cancer patients. Palliat Med 1999;13:183-196.

70. Mercadante S. The use of anti-inflammatory drugs in cancer pain. Cancer Treat Rev 2001; 27:51-61.

71. in t'Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-1521.

Lema MJ. Emerging options with coxib therapy. Cleve Clin J Med 2002;69:SI76-84.